雷诺嗪在大鼠前列腺癌体内模型中的抗转移作用及人前列腺组织中电压门控钠通道蛋白的表达
研究使用Dunning大鼠前列腺癌模型,皮下接种Mat-LyLu细胞后灌胃给予雷诺嗪,观察原发瘤和转移灶变化,并用人类前列腺组织芯片检测电压门控钠通道蛋白表达。结果显示雷诺嗪2.5和5 µM使肺转移灶数量最多减少63%,原发瘤发生未受影响;癌组织电压门控钠通道蛋白表达显著高于非癌组织,但与前列腺特异性抗原或Gleason评分无相关性。作者认为Nav1.7表达可能作为转移性前列腺癌的功能性生物标志物,电压门控钠通道阻滞剂可能用作抗转移药物。
要点
- 雷诺嗪2.5和5 µM使大鼠前列腺癌肺转移灶数量最多减少63%。
- 雷诺嗪未影响原发瘤发生。
- 癌组织电压门控钠通道蛋白表达显著高于非癌组织,与前列腺特异性抗原或Gleason评分无相关性。
核心结论
- 雷诺嗪抑制转移,且到达转移部位的是Nav1.7蛋白水平特别高的细胞亚群。
- 作者认为Nav1.7表达可能作为转移性前列腺癌的功能性生物标志物,电压门控钠通道阻滞剂可能用作抗转移药物。
研究设计与样本
- 使用Dunning大鼠前列腺癌模型,向Copenhagen大鼠皮下接种Mat-LyLu细胞后,经灌胃全身给予雷诺嗪,观察原发瘤和转移灶的发生。
- 使用人类前列腺组织芯片确定癌组织与非癌组织中电压门控钠通道蛋白的表达。
- 检索多个公共数据库比较「正常」组织与前列腺癌组织中Nav1.7/SCN9A表达水平。
主要发现
- 雷诺嗪(2.5和5 µM)使肺转移灶数量最多减少63%。
- 原发瘤发生未受影响。
- 雷诺嗪还降低了转移灶中表达Nav1.7(前列腺癌中表达的主要电压门控钠通道亚型)的细胞百分比,但表达水平更高。
- 在前列腺组织芯片中,癌组织电压门控钠通道蛋白表达显著高于非癌组织。
- 电压门控钠通道表达与前列腺特异性抗原或Gleason评分之间无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Voltage-gated Na+ channels (VGSCs) are functionally upregulated in rat and human prostate cancer (PCa) where channel activity promotes cellular invasiveness in vitro and metastasis in vivo. Ranolazine is a clinically used VGSC inhibitor/anti-anginal drug, which has been shown previously to inhibit breast cancer metastasis in vivo. METHODS: Using the Dunning model of rat PCa, the effect of ranolazine applied systemically (by gavage) was tested on the development of primary tumours and metastases following subcutaneous inoculation of Mat-LyLu cells into Copenhagen rats. In addition, human prostate tissue microarrays were used to determine VGSC protein expression in cancerous versus non-cancerous tissue. Several public databases were searched to compare Nav1.7/ SCN9A expression levels in 'normal' vs. PCa tissues. RESULTS: Ranolazine (2.5 and 5 µM) decreased the number of lung metastases by up to 63%. In contrast, primary tumourigenesis was not affected. Ranolazine also reduced the percentage of cells in the metastases expressing Nav1.7, the main VGSC subtype expressed in PCa, but the expression level was higher. In prostate tissue microarrays, VGSC protein expression was significantly higher in cancerous versus non-cancerous tissue. There was no correlation between the VGSC expression and either prostate-specific antigen or Gleason score. In public databases, little information could be found on Nav1.7 protein expression in PCa. In addition, the database information on Nav1.7 mRNA (SCN9A) expression levels did not correlate with previously reported upregulation in PCa cells and tissues. CONCLUSIONS: The main conclusions were (i) ranolazine inhibited metastasis and (ii) it was a subpopulation of cells with particularly high levels of Nav1.7 protein that reached the metastatic sites. These data extend earlier studies and suggest that Nav1.7 expression could serve as a functional biomarker of metastatic PCa and that VGSC blockers may be useful as anti-metastatic agents.
引用
- Bugan I, Kucuk S, Karagoz Z, et al. Anti-metastatic effect of ranolazine in an in vivo rat model of prostate cancer, and expression of voltage-gated sodium channel protein in human prostate. Prostate Cancer Prostatic Dis. 2019. PMID: 30894674. doi:10.1038/s41391-019-0128-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。